A detailed history of Shell Asset Management CO transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 138,958 shares of LYEL stock, worth $209,826. This represents 0.01% of its overall portfolio holdings.

Number of Shares
138,958
Previous 143,991 3.5%
Holding current value
$209,826
Previous $279,000 11.11%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.71 - $3.07 $8,606 - $15,451
-5,033 Reduced 3.5%
138,958 $310,000
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $60,009 - $101,454
-43,172 Reduced 23.07%
143,991 $279,000
Q3 2023

Nov 08, 2023

SELL
$1.45 - $3.35 $4,702 - $10,864
-3,243 Reduced 1.7%
187,163 $275,000
Q2 2023

Jul 28, 2023

BUY
$1.89 - $3.86 $359,867 - $734,967
190,406 New
190,406 $605,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $374M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.